Drug Type Fusion protein |
Synonyms QLS-31901 |
Target |
Action inhibitors |
Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors), TGF-β inhibitors(Transforming growth factor beta inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced cancer | Phase 1 | China | 25 May 2021 |